The surgical treatment of rheumatoid arthritis: a new era?

  title={The surgical treatment of rheumatoid arthritis: a new era?},
  author={Elena Nikiphorou and Sujith Konan and Alexander J Macgregor and F. S. Haddad and Adam Young},
  journal={The bone \& joint journal},
  volume={96-B 10},
There has been an in increase in the availability of effective biological agents for the treatment of rheumatoid arthritis as well as a shift towards early diagnosis and management of the inflammatory process. This article explores the impact this may have on the place of orthopaedic surgery in the management of patients with rheumatoid arthritis. 
Surgical Intervention for Rheumatoid Arthritis and Complication Risks
Abstract There is a global trend toward a decline in surgical intervention for rheumatoid arthritis, over a similar period during which medical management has improved. However, surgery continues toExpand
Non-drug Treatments
This chapter will provide an overview of these crucial non-pharmacological management approaches to treating inflammatory arthritis. Expand
Incidence and Complication Rates for Total Hip Arthroplasty in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Across Four Decades
There remains room for further improvement to postoperative outcomes through RA-specific management, as medical management of patients with RA has reduced the need for THA, while postoperative medical and surgical management has improved some postoperatively outcomes. Expand


Orthopaedic surgery in patients with rheumatoid arthritis: a shift towards more frequent and earlier non-joint-sacrificing surgery.
A cross sectional study on the use of orthopaedic surgery in RA is performed to provide data on types of procedures and evolution of timing and type of surgery. Expand
Hand and Foot Surgery Rates in Rheumatoid Arthritis Have Declined From 1986 to 2011, but Large‐Joint Replacement Rates Remain Unchanged: Results From Two UK Inception Cohorts
To assess whether there have been any secular changes in orthopedic interventions in patients with rheumatoid arthritis (RA) since 1986, as examined in 2 early rheumatoid arthritis (RA) inceptionExpand
Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
The results confirm the earlier concept that triple therapy with combinations of DMARDs contributes to an improved long-term radiologic outcome in patients with early and clinically active RA. Expand
Declining use of orthopedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment.
Reconstructive surgeries are common in RA, although patients diagnosed after 1985 are less likely to require joint surgery and may reflect trends in medical disease management and have importance for health care resource utilization planning. Expand
Prospects for autoimmune disease: Research advances in rheumatoid arthritis.
Reconstructive surgery will become increasingly unnecessary and the morbidity, economic burden, and mortality due to RA will be reduced substantially. Expand
Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.
The radiological superiority of biological compared with conventional combination therapy did not translate into better work loss outcomes in patients with early RA who had experienced an insufficient response to methotrexate. Expand
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
A strategy of intensive outpatient management of rheumatoid arthritis substantially improves disease activity, radiographic disease progression, physical function, and quality of life at no additional cost. Expand
Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study.
Findings show that a delay in instituting therapy with second-line agents, even a 9 month delay, has significant effects on longterm patient outcome, and provides strong evidence in support of early therapy in RA. Expand
The Effectiveness of Early Treatment with Second-Line Antirheumatic Drugs
The first-year results of a randomized clinical trial in which the delayed and the immediate introduction of SAARDs were compared are described and the consequences of ignoring the treatment pyramid for patients with recent-onset rheumatoid arthritis are investigated. Expand
Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study.
The results indicate the existence of a therapeutic window in RA within the first 2 years of the disease. Expand